Nycomed and Amersham to Merge
Executive Summary
Since its failed merger with generics giant Ivax two years ago, Nycomed has been looking for a partner to help it out of the morass of a difficult contrast media market. With larger purchasers on the rise, prices went south, catching Nycomed off guard. With Amersham, the company will be able to broaden its product line, offering both wider product choice to customers and a more efficient cost structure.